COO Valuation Metrics
COO Stock Price Metrics
COO Dividend Metrics
COO Growth Rate Metrics
COO Discounted Cash Flow Metrics
| Fair Value Price | $58.78 |
| Margin of Safety | (13.40%) |
COO Revenue Metrics
COO PE Ratio Metrics
| PE Ratio | 57.53 |
| PE Ratio Avg TTM | 37.10 |
| PE Ratio Avg 3Y | 47.50 |
| Current VS TTM Avg | +55.09% |
| Current VS 3Y Avg | +21.10% |
| Current VS 5Y Avg | +83.93% |
COO PS Ratio Metrics
| PS Ratio | 3.13 |
| PS Ratio Avg TTM | 3.55 |
| PS Ratio Avg 3Y | 4.51 |
| Current VS TTM Avg | -11.71% |
| Current VS 3Y Avg | -30.55% |
| Current VS 5Y Avg | -38.58% |
COO PB Ratio Metrics
| PB Ratio | 1.61 |
| PB Ratio Avg TTM | 1.74 |
| PB Ratio Avg 3Y | 2.16 |
| Current VS TTM Avg | -7.35% |
| Current VS 3Y Avg | -25.51% |
| Current VS 5Y Avg | -31.43% |
COO Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 23.24 |
| PFCF Ratio Avg TTM | 34.01 |
| PFCF Ratio Avg 3Y | 71.59 |
| Current VS TTM Avg | -31.67% |
| Current VS 3Y Avg | -67.54% |
| Current VS 5Y Avg | -59.95% |
COO Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.34 |
| Debt/Equity Ratio Avg TTM | 0.33 |
| Debt/Equity Ratio Avg 3Y | 0.35 |
| Current VS TTM Avg | +3.03% |
| Current VS 3Y Avg | -2.16% |
| Current VS 5Y Avg | -4.67% |
COO PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 0.83 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
COO FCF Yield
| FCF Yield | 4.30% |
| FCF Yield Avg TTM | 3.02% |
| FCF Yield Avg 3Y | 1.90% |
| Current VS TTM Avg | +42.20% |
| Current VS 3Y Avg | +125.88% |
| Current VS 5Y Avg | +91.94% |
COO Earnings Yield
| Earnings Yield | 1.74% |
| Earnings Yield Avg TTM | 2.75% |
| Earnings Yield Avg 3Y | 2.25% |
| Current VS TTM Avg | -36.66% |
| Current VS 3Y Avg | -22.78% |
| Current VS 5Y Avg | -86.33% |
COO EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 31.25 |
| Ev/Ebit Ratio Avg TTM | 23.67 |
| Ev/Ebit Ratio Avg 3Y | 31.83 |
| Current VS TTM Avg | +32.03% |
| Current VS 3Y Avg | -1.82% |
| Current VS 5Y Avg | -12.37% |
COO EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 17.97 |
| Ev/Ebitda Ratio Avg TTM | 15.95 |
| Ev/Ebitda Ratio Avg 3Y | 20.14 |
| Current VS TTM Avg | +12.64% |
| Current VS 3Y Avg | -10.76% |
| Current VS 5Y Avg | -18.02% |
COO EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.25 |
| Ev/Assets Ratio Avg TTM | 1.36 |
| Ev/Assets Ratio Avg 3Y | 1.62 |
| Current VS TTM Avg | -8.26% |
| Current VS 3Y Avg | -22.91% |
| Current VS 5Y Avg | -28.45% |
COO EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.68 |
| Ev/Sales Ratio Avg TTM | 4.15 |
| Ev/Sales Ratio Avg 3Y | 5.16 |
| Current VS TTM Avg | -11.30% |
| Current VS 3Y Avg | -28.71% |
| Current VS 5Y Avg | -36.63% |
COO Current Ratio Metrics
| Current Ratio | 1.89 |
| Current Ratio Avg TTM | 1.90 |
| Current Ratio Avg 3Y | 1.69 |
| Current VS TTM Avg | -0.53% |
| Current VS 3Y Avg | +11.83% |
| Current VS 5Y Avg | +13.06% |
COO Quick Ratio Metrics
| Quick Ratio | 1.13 |
| Quick Ratio Avg TTM | 1.13 |
| Quick Ratio Avg 3Y | 0.99 |
| Current VS TTM Avg | +0.44% |
| Current VS 3Y Avg | +14.14% |
| Current VS 5Y Avg | +15.70% |
COO ROIC Metrics
| ROIC | 3.98% |
| ROIC Avg 3Y | 3.90% |
| ROIC Avg 5Y | 4.29% |
| Current VS 3Y Avg | +2.05% |
| Current VS 5Y Avg | -7.33% |
| Current VS 10Y Avg | -26.86% |
COO Return on Assets Metrics
| ROA | 3.02 |
| ROA Avg TTM | 3.10 |
| ROA Avg 3Y | 3.02 |
| Current VS TTM Avg | -2.74% |
| Current VS 3Y Avg | -0.08% |
| Current VS 5Y Avg | -60.85% |
COO Return on Equity Metrics
| ROE | 4.55 |
| ROE Avg TTM | 4.70 |
| ROE Avg 3Y | 4.67 |
| Current VS TTM Avg | -3.19% |
| Current VS 3Y Avg | -2.57% |
| Current VS 5Y Avg | -59.45% |
COO Net Profit Margin Metrics
| Net Profit Margin | 9.16% |
| Net Profit Margin Avg TTM | 9.62% |
| Net Profit Margin Avg 3Y | 9.77% |
| Current VS TTM Avg | -4.73% |
| Current VS 3Y Avg | -6.24% |
| Current VS 5Y Avg | -63.27% |
Last Updated: Sunday, June 14, 2026
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White